Educational information
This video was distributed by our partner, ReachMD, a leading online learning platform for physicians and other healthcare professionals.
Faculty
- Prof. Ileana L. Piña, MD - Clinical Professor of Medicine, College of Medicine, Central Michigan University, Mount Pleasant, MI, USA
- Prof. Patrick Rossignol, MD, PhD - Professor of Therapeutics, Université de Lorraine, Nancy, France
Disclosures
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of PACE-cme.
Funding
This activity is supported by an independent educational grant from CSL Vifor.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Overview
In HF, the use of MRAs is often delayed despite being a crucial part of medical therapy. Prof. Ileana Piña and Prof. Patrick Rossignol discuss approaches to the clinical stigma surrounding the use of MRAs, as well as management strategies to better ensure the best medical therapy possible for patients with HF.
